Recent investigations have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR activator therapies and dopaminergic communication. While GLP agonists are commonly employed for managing type 2 diabetes, their emerging impacts on reward circuits,